Industry & Policy News

[Science Insider] “This is a clue and it’s an important one,” says scientist overseeing the global health agency’s probe into what sparked the pandemic.

[Science Insider] The number of high-containment labs studying the deadliest known pathogens is booming. A new analysis warns the growing number of labs is raising risks of an accidental release or misuse of germs such as the Ebola and Nipah viruses.

[Tenax Therapeutics, Inc.] Tenax Therapeutics, Inc. announced that the company has been issued a patent by the United States Patent and Trademark Office with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.

[Nature] Officials at the US Environmental Protection Agency (EPA) and local, state and federal agencies, as well as the train’s operator, Norfolk Southern, have been monitoring water and air quality in the town — but community members haven’t been satisfied with official reports claiming that levels of the chemicals are low and safe.

[Novartis] Novartis announced the US FDA granted approval for Tafinlar® + Mekinist® for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

[Gene Online (OncoC4)] BioNTech and OncoC4 are partnering up to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392, as a monotherapy or combination therapy for various cancers.